Description
Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability ofLIQ861 in subjects who have WHO Group 1 & 3 PH. Cohort A will include approximately 60 subjects who have WHO Group 3 Pulmonary Hypertension associated with interstitial lung disease (PH-ILD). Additional cohorts from wither Group 1 or Group 3 may be defined in the future protocol amendments. Scheduled study visits to the clinic will occur at Screening, Baseline, Week 8, 16, 24 and 52.
